{"transactions":[{"id":740044,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-06-12T20:25:08.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":9250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":9250,"derivative":{"exercise_price":13.22,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":9250},"source":{"system":"sec-edgar","filing":"0001182471-26-000002","document":"form4-06122026_080603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000118247126000002/form4-06122026_080603.xml","form_type":"4"}},{"id":1142916,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-05-19T22:48:48.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date."}],"balance_after":130000,"derivative":{"exercise_price":0.4017,"expiration_date":"2035-05-14","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001415889-25-013719","document":"form4-05192025_100545.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925013719/form4-05192025_100545.xml","form_type":"4"}},{"id":1477392,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-06-17T20:13:24.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 14, 2024 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 14, 2024, subject to the Reporting Person providing continuous service through such date."}],"balance_after":130000,"derivative":{"exercise_price":2.36,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001415889-24-017162","document":"form4-06172024_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588924017162/form4-06172024_080620.xml","form_type":"4"}},{"id":1503703,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-23T22:18:06.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":36490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest in 12 equal monthly installments from date of grant of May 22, 2024."}],"balance_after":36490,"derivative":{"exercise_price":4.63,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":36490},"source":{"system":"sec-edgar","filing":"0001415889-24-014378","document":"form4-05232024_100501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000141588924014378/form4-05232024_100501.xml","form_type":"4"}},{"id":1545479,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:16:19.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":225000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":8.14,"expiration_date":"2028-01-30","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000950170-24-042619","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1182471/000095017024042619/ownership.xml","form_type":"4"}},{"id":1545478,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:16:19.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":12.06,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-24-042619","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1182471/000095017024042619/ownership.xml","form_type":"4"}},{"id":1545477,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:16:19.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":16.47,"expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-24-042619","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1182471/000095017024042619/ownership.xml","form_type":"4"}},{"id":1545476,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:16:19.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":31.93,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000950170-24-042619","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1182471/000095017024042619/ownership.xml","form_type":"4"}},{"id":1545475,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:16:19.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":15.2,"expiration_date":"2032-03-02","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000950170-24-042619","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1182471/000095017024042619/ownership.xml","form_type":"4"}},{"id":1545474,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:16:19.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":78407,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the \"Offer Price\") (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.69,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":78407},"source":{"system":"sec-edgar","filing":"0000950170-24-042619","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1182471/000095017024042619/ownership.xml","form_type":"4"}},{"id":1545473,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T16:16:19.000Z","date":"2024-04-05","kind":"other","planned":false,"acquired":false,"shares":2769168,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to a Rollover Agreement between, inter alia, Mr. Rieflin, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc. a wholly-owned subsidiary of Parent (\"Purchaser\"), in exchange for shares in Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Rieflin Family Trust U/A 4/3/00."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-042619","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182471/000095017024042619/ownership.xml","form_type":"4"}},{"id":1545472,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T16:16:19.000Z","date":"2024-04-05","kind":"other","planned":false,"acquired":false,"shares":5172,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to a Rollover Agreement between, inter alia, Mr. Rieflin, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc. a wholly-owned subsidiary of Parent (\"Purchaser\"), in exchange for shares in Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-042619","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182471/000095017024042619/ownership.xml","form_type":"4"}},{"id":1556301,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-01T22:48:55.000Z","date":"2024-03-28","kind":"grant","planned":false,"acquired":true,"shares":11871,"price":7.58,"value":89982.18,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of $90,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2024 with the first installment vesting on March 31, 2024, provided that the reporting person is in service as a director on each such vesting date."}],"balance_after":11871,"derivative":{"exercise_price":8.98,"expiration_date":"2034-03-27","underlying":"Common Stock","underlying_shares":11871},"source":{"system":"sec-edgar","filing":"0001415889-24-009605","document":"form4-04012024_100439.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000141588924009605/form4-04012024_100439.xml","form_type":"4"}},{"id":1784766,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-09-08T20:27:11.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On September 6, 2023, to align with benchmarking data, the issuer's Compensation Committee amended the Non-Employee Director Compensation Policy to increase the annual equity grant to non-employee directors. The Reporting Person was granted an option to purchase 65,000 shares on June 16, 2023, prior to the amendment of the policy. This additional option grant aligns the Reporting Person's total 2023 grants with the updated policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Persons failure to be re-elected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date."}],"balance_after":55000,"derivative":{"exercise_price":3.19,"expiration_date":"2033-09-07","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-23-048786","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919123048786/doc4.xml","form_type":"4"}},{"id":1849698,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-06-20T20:51:22.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected\nor the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person\nproviding continuous service through such date."}],"balance_after":65000,"derivative":{"exercise_price":3.19,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-23-038449","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919123038449/doc4.xml","form_type":"4"}},{"id":1878150,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-25T23:00:34.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":12940,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest on the earlier of (i) May 24, 2024, or (ii) one day prior to the date of the Issuer's next annual meeting of stockholders to be held in 2024, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":12940,"derivative":{"exercise_price":20.93,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":12940},"source":{"system":"sec-edgar","filing":"0001209191-23-032297","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919123032297/doc4.xml","form_type":"4"}},{"id":1894959,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-12T17:52:43.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":78407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date."}],"balance_after":78407,"derivative":{"exercise_price":3.69,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":78407},"source":{"system":"sec-edgar","filing":"0001209191-23-029189","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182471/000120919123029189/doc4.xml","form_type":"4"}},{"id":1922299,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-11T00:10:09.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":6026,"price":14.52,"value":87497.52,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of $87,500."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2023 with the first installment vesting on March 31, 2023, provided that the reporting person is in service as a director on each such vesting date."}],"balance_after":6026,"derivative":{"exercise_price":18.35,"expiration_date":"2033-03-30","underlying":"Common Stock","underlying_shares":6026},"source":{"system":"sec-edgar","filing":"0001209191-23-023945","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919123023945/doc4.xml","form_type":"4"}},{"id":2236204,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-06-10T20:20:27.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 8, 2022 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected\nor the Reporting Person not standing for re-election); or (b) the first anniversary of June 8, 2022, subject to the Reporting Person\nproviding continuous service through such date."}],"balance_after":65000,"derivative":{"exercise_price":5.31,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-22-035879","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919122035879/doc4.xml","form_type":"4"}},{"id":2255274,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T22:18:04.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest on the earlier of (i) May 25, 2023, or (ii) one day prior to the date of the Issuer's next annual meeting of stockholders to be held in 2023, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":8500,"derivative":{"exercise_price":13.64,"expiration_date":"2032-05-24","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-22-032319","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919122032319/doc4.xml","form_type":"4"}},{"id":2308315,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-04T21:58:26.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":5207,"price":16.8,"value":87477.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of $87,500."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2022 with the first installment vesting on March 31, 2022, provided that the reporting person is in service as a director on each such vesting date."}],"balance_after":5207,"derivative":{"exercise_price":21.99,"expiration_date":"2032-03-30","underlying":"Common Stock","underlying_shares":5207},"source":{"system":"sec-edgar","filing":"0001209191-22-022616","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919122022616/doc4.xml","form_type":"4"}},{"id":2350149,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-04T16:11:45.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis."}],"balance_after":80000,"derivative":{"exercise_price":15.2,"expiration_date":"2032-03-02","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-22-016213","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182471/000120919122016213/doc4.xml","form_type":"4"}},{"id":2655860,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-25T00:17:41.000Z","date":"2021-05-28","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest on the earlier of (i) May 28, 2022, or (ii) one day prior to the date of the Issuer's next annual meeting of stockholders to be held in 2022, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":7500,"derivative":{"exercise_price":19.3,"expiration_date":"2031-05-27","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001593968-21-001695","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000159396821001695/primary_01.xml","form_type":"4"}},{"id":2779039,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-18T20:22:45.000Z","date":"2021-03-17","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest over a four-year period commencing January 1, 2021, with 1/48th of the shares vesting on a monthly basis."}],"balance_after":80000,"derivative":{"exercise_price":31.93,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-21-021930","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182471/000120919121021930/doc4.xml","form_type":"4"}},{"id":2971357,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-20T20:56:39.000Z","date":"2020-11-19","kind":"purchase","acquired":true,"shares":10000,"price":16.22,"value":162200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.90 to $16.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":18000,"source":{"system":"sec-edgar","filing":"0001593968-20-002227","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000159396820002227/primary_01.xml","form_type":"4"}},{"id":3104339,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-19T21:44:09.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest on the earlier of (i) June 18, 2021, or (ii) one day prior to the date of the Issuer's next annual meeting of stockholders to be held in 2021, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":7500,"derivative":{"exercise_price":28.27,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-20-038011","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919120038011/doc4.xml","form_type":"4"}},{"id":3286472,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-06T20:03:31.000Z","date":"2020-02-04","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest over a four-year period commencing January 1, 2020, with 1/48th of the shares vesting on a monthly basis."}],"balance_after":75000,"derivative":{"exercise_price":16.47,"expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-20-007323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182471/000120919120007323/doc4.xml","form_type":"4"}},{"id":3382146,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-11-04T23:54:32.000Z","date":"2019-11-04","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees, for which the Reporting\nPerson is co-Trustee."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16666},"source":{"system":"sec-edgar","filing":"0001209191-19-055033","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919119055033/doc4.xml","form_type":"4"}},{"id":3382145,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-11-04T23:54:32.000Z","date":"2019-11-04","kind":"exercise","acquired":false,"shares":260344,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees, for which the Reporting\nPerson is co-Trustee."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":43390},"source":{"system":"sec-edgar","filing":"0001209191-19-055033","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919119055033/doc4.xml","form_type":"4"}},{"id":3382144,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-04T23:54:32.000Z","date":"2019-11-04","kind":"purchase","acquired":true,"shares":8000,"price":12,"value":96000.0,"ownership":{"direct":true},"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001209191-19-055033","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919119055033/doc4.xml","form_type":"4"}},{"id":3382143,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-04T23:54:32.000Z","date":"2019-11-04","kind":"exercise","acquired":true,"shares":16666,"ownership":{"direct":false,"nature":"By Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees, for which the Reporting\nPerson is co-Trustee."}],"balance_after":76722,"source":{"system":"sec-edgar","filing":"0001209191-19-055033","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919119055033/doc4.xml","form_type":"4"}},{"id":3382142,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-04T23:54:32.000Z","date":"2019-11-04","kind":"exercise","acquired":true,"shares":43390,"ownership":{"direct":false,"nature":"By Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees, for which the Reporting\nPerson is co-Trustee."}],"balance_after":60056,"source":{"system":"sec-edgar","filing":"0001209191-19-055033","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919119055033/doc4.xml","form_type":"4"}},{"id":3383611,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-11-01T22:38:21.000Z","date":"2019-10-30","kind":"grant","acquired":true,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 12 equal monthly installments from the vesting commencement date."}],"balance_after":3333,"derivative":{"exercise_price":12,"expiration_date":"2029-10-29","underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001209191-19-054776","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919119054776/doc4.xml","form_type":"4"}},{"id":3383610,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-11-01T22:38:21.000Z","date":"2019-10-30","kind":"grant","acquired":true,"shares":15334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 12 equal monthly installments from the vesting commencement date."}],"balance_after":15334,"derivative":{"exercise_price":12,"expiration_date":"2029-10-29","underlying":"Common Stock","underlying_shares":15334},"source":{"system":"sec-edgar","filing":"0001209191-19-054776","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919119054776/doc4.xml","form_type":"4"}},{"id":3558392,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series B Preferred Stock","published_at":"2019-04-10T11:21:58.000Z","date":"2019-04-08","kind":"exercise","acquired":false,"shares":6668,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Every two shares of Series A preferred stock and Series B preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering.  These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Every two shares of Series A preferred stock and Series B preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering.  These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Every two shares of Series A preferred stock and Series B preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering.  These shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Rieflin Family Trust U/A 4/3/00."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6668},"source":{"system":"sec-edgar","filing":"0001209191-19-024198","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1182471/000120919119024198/doc4.xml","form_type":"4"}},{"id":3558391,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series A Preferred Stock","published_at":"2019-04-10T11:21:58.000Z","date":"2019-04-08","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Every two shares of Series A preferred stock and Series B preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering.  These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Every two shares of Series A preferred stock and Series B preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering.  These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Every two shares of Series A preferred stock and Series B preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering.  These shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Rieflin Family Trust U/A 4/3/00."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-19-024198","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182471/000120919119024198/doc4.xml","form_type":"4"}},{"id":3558390,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2019-04-10T11:21:58.000Z","date":"2019-04-08","kind":"exercise","acquired":true,"shares":56668,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Every two shares of Series A preferred stock and Series B preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering.  These shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Rieflin early exercised certain shares of common stock, of which (i) 44,531 shares of common stock granted on January 27, 2016 remain unvested and (ii) 103,906 shares of common stock granted on January 20, 2017 remain unvested."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Rieflin Family Trust U/A 4/3/00."}],"balance_after":2769168,"source":{"system":"sec-edgar","filing":"0001209191-19-024198","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182471/000120919119024198/doc4.xml","form_type":"4"}}]}